Jonathan Fisher

Jonathan Fisher leads research on gamma-delta T cell-based immunotherapies for pediatric solid tumors, developing off-the-shelf cellular therapy platforms that could overcome the manufacturing limitations of autologous CAR-T cells in young children. His work engineering innate immune cells for anti-tumor activity has produced novel therapeutic candidates for neuroblastoma and other pediatric malignancies. He contributes to international efforts to broaden the immunotherapy toolkit available for children with cancer.